Background: injectable medicines are increasingly used to manage abnormal levels of lipids, which is a major risk factor for cardiovascular events. enhancing our understanding of patients' perceptions of these injectables, can inform practice with the aim of increasing uptake and medication adherence. aim: to explore patient's experiences of using injectables and to identify potential facilitators and barriers to using injectable therapies in dyslipidaemia. design: a qualitative descriptive study using semi-structured interviews was conducted with patients who were using injectables to manage their cardiovascular conditions. methods: a total of 56 patients, 30 from the united kingdom and 26 from italy, were interviewed online from november 2020 to June 2021. interviews were transcribed and schematic content analysis performed. results: four distinct themes emerged from interviews with patients and caregivers: (i) their behaviours and personal beliefs; (ii) knowledge and education about injectable medication; (iii) clinical skills and previous experiences and (iv) organizational and governance. participants expressed initial fears such as needle phobia, and their concerns about commencing therapy were compounded by a lack of accessible information. however, patients' pre-existing knowledge of lipid lowering medication, previous experience with statins and history of adverse side effects informed their decision-making regarding using injectables. organization and governance-related issues were primarily around the distribution and management of medication supply within primary care, and the lack of a standardized clinical support monitoring system. conclusion: changes are needed in clinical practice to better educate and support patients to improve the uptake of injectables and optimize their use of these medications in the management of dyslipidaemia. Impact: this study suggests that injectable therapies were acceptable to people with cardiovascular disease. however, healthcare professionals need to play a key role in improving education and providing support to aid patients' decision-making regarding commencing and adhering to injectable therapies. reporting method: the study adhered to the consolidated criteria for reporting qualitative research. patient or public contribution: there was no patient or public contribution.

Lee, G.a., Durante, A., Baker, E.e., Vellone, E., Caggianelli, G., Dellafiore, F., et al. (2023). Patients' perceptions on the facilitators and barriers using injectable therapies in dyslipidaemia: An empirical qualitative descriptive international study. JOURNAL OF ADVANCED NURSING, 79(12), 4687-4696 [10.1111/jan.15739].

Patients' perceptions on the facilitators and barriers using injectable therapies in dyslipidaemia: An empirical qualitative descriptive international study

Durante, Angela;Vellone, Ercole
;
Dellafiore, Federica;
2023-12-01

Abstract

Background: injectable medicines are increasingly used to manage abnormal levels of lipids, which is a major risk factor for cardiovascular events. enhancing our understanding of patients' perceptions of these injectables, can inform practice with the aim of increasing uptake and medication adherence. aim: to explore patient's experiences of using injectables and to identify potential facilitators and barriers to using injectable therapies in dyslipidaemia. design: a qualitative descriptive study using semi-structured interviews was conducted with patients who were using injectables to manage their cardiovascular conditions. methods: a total of 56 patients, 30 from the united kingdom and 26 from italy, were interviewed online from november 2020 to June 2021. interviews were transcribed and schematic content analysis performed. results: four distinct themes emerged from interviews with patients and caregivers: (i) their behaviours and personal beliefs; (ii) knowledge and education about injectable medication; (iii) clinical skills and previous experiences and (iv) organizational and governance. participants expressed initial fears such as needle phobia, and their concerns about commencing therapy were compounded by a lack of accessible information. however, patients' pre-existing knowledge of lipid lowering medication, previous experience with statins and history of adverse side effects informed their decision-making regarding using injectables. organization and governance-related issues were primarily around the distribution and management of medication supply within primary care, and the lack of a standardized clinical support monitoring system. conclusion: changes are needed in clinical practice to better educate and support patients to improve the uptake of injectables and optimize their use of these medications in the management of dyslipidaemia. Impact: this study suggests that injectable therapies were acceptable to people with cardiovascular disease. however, healthcare professionals need to play a key role in improving education and providing support to aid patients' decision-making regarding commencing and adhering to injectable therapies. reporting method: the study adhered to the consolidated criteria for reporting qualitative research. patient or public contribution: there was no patient or public contribution.
dic-2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/45
English
barriers and facilitators
cardiovascular disease
injectable therapies
patient perceptions
Lee, G.a., Durante, A., Baker, E.e., Vellone, E., Caggianelli, G., Dellafiore, F., et al. (2023). Patients' perceptions on the facilitators and barriers using injectable therapies in dyslipidaemia: An empirical qualitative descriptive international study. JOURNAL OF ADVANCED NURSING, 79(12), 4687-4696 [10.1111/jan.15739].
Lee, Ga; Durante, A; Baker, Ee; Vellone, E; Caggianelli, G; Dellafiore, F; Khan, M; Khatib, R
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Journal of Advanced Nursing - 2023 - Lee - Patients perceptions on the facilitators and barriers using injectable.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.03 MB
Formato Adobe PDF
1.03 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/343943
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact